Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tanox' HIV drug candidate, TNX-355, has generated positive data at week 48 of a phase II clinical trial, demonstrating that the drug produces sustained viral load reductions.
Subscribe to our email newsletter
The new results show that HIV-infected patients who received TNX-355 maintained a considerably greater reduction in viral load than patients given placebo in combination with an optimized background regimen.
The 48-week results also showed that patients who received TNX-355 in combination with the background regimen experienced a statistically significant increase in CD4+ cells compared to those who received placebo plus the background regimen.
“The 48-week results demonstrate the ability of TNX-355 to produce durable viral-load suppression, while also providing a clinically meaningful immunologic response,” said Danong Chen, Tanox president and CEO. “These data suggest that TNX-355 has the potential to be a first-in-class therapy to advance HIV care for treatment-experienced patients.”